Using mice knocked-out for the E-selectin gene and a therapeutically relevant E-selectin antagonist (GMI-1271/Uproleselan), we have recently discovered that E-selectin also regulates malignant AML cells by influencing therapy response. This evidence concerns the gene SELE and acute myeloid leukemia.